Answers are grounded in this paper and cite their sources.
Background/Objectives: Antimicrobial resistance (AMR) is one of the most critical global public health challenges, particularly in low- and middle-income countries where antimicrobial consumption remains high. Brazil has historically exhibited elevated antimicrobial consumption in community settings, despite progressive regulatory interventions over the past decade. This article provides a pharmacoepidemiological overview of antimicrobial use, regulatory measures, and resistance-related challenges in Brazil, with implications for comparable settings. Methods: A narrative review was conducted using PubMed/MEDLINE, Scopus, and SciELO, covering publications from January 2010 to December 2025 and restricted to English- and Portuguese-language sources. Official data from the National System for the Management of Controlled Products (SNGPC), ANVISA bulletins, BR-GLASS reports, and national AMR surveillance initiatives were also incorporated. Results: Between 2014 and 2021, 355.7 million antimicrobial sales records were captured in the SNGPC (of 532.5 million controlled-product records; 2014 to November 2021). Amoxicillin (24.1%), azithromycin (12.2%), ciprofloxacin (9.4%), and cephalexin (7.7%) were the best-selling agents, and the top ten accounted for 76.5% of antimicrobial sales. DDD-based consumption increased by approximately 30% from 2014 to 2019, and 24 of 53 systemic antimicrobials (45%) were classified as WHO Watch, and Watch accounted for 45.5–49.9% of DDD-based consumption across regions in 2019. The COVID-19 pandemic was temporally associated with a 152% increase in azithromycin consumption (from 1.40 to 3.53 DDD/1000 inhabitants/day between February and July 2020). Carbapenem resistance in Klebsiella pneumoniae increased from 26% to 52% and remained elevated afterwards; this temporal association does not establish causality. Among Brazilian hospitals with adult intensive care units, fewer than 50% had a formal antimicrobial stewardship program. Conclusions: Regulatory measures have strengthened prescription requirements and reduced non-prescription sales; however, their impact on inappropriate clinical use and resistance trends remains heterogeneous. Strengthening antimicrobial stewardship, improving microbiological diagnostic capacity, and integrating surveillance systems are essential priorities for mitigating AMR in Brazil and in comparable healthcare settings.
No takes yet. Share an insight, caveat, or question.
Paiva et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: